Literature DB >> 23598157

Opioid receptors: toward separation of analgesic from undesirable effects.

Ping-Yee Law1, Patricia H Reggio, Horace H Loh.   

Abstract

The use of opioid analgesics for pain has always been hampered by their many side effects; in particular, the addictive liability associated with chronic use. Recently, attempts to develop analgesic agents with reduced side effects have targeted either the putative opioid receptor splice variants or the receptor hetero-oligomers. This review discusses the potential for receptor splice variant- and the hetero-oligomer-based discovery of new opioid analgesics. We also examine an alternative approach of using receptor mutants for pain management. Finally, we discuss the role of the biased agonism observed and the recently reported opioid receptor crystal structures in guiding the future development of opioid analgesics.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23598157      PMCID： PMC3665630          DOI： 10.1016/j.tibs.2013.03.003

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN： 0968-0004            Impact factor:   13.807


  93 in total

1.  Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.

Authors:  Natalie R Lenard; David J Daniels; Philip S Portoghese; Sandra C Roerig
Journal:  Eur J Pharmacol       Date:  2007-03-03       Impact factor: 4.432

2.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

3.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

Authors:  Vadim Cherezov; Daniel M Rosenbaum; Michael A Hanson; Søren G F Rasmussen; Foon Sun Thian; Tong Sun Kobilka; Hee-Jung Choi; Peter Kuhn; William I Weis; Brian K Kobilka; Raymond C Stevens
Journal:  Science       Date:  2007-10-25       Impact factor: 47.728

Review 4.  Kappa receptor bivalent ligands.

Authors:  Xuemei Peng; John L Neumeyer
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

5.  Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence.

Authors:  Joseph A Kim; Selena Bartlett; Li He; Carsten K Nielsen; Amy M Chang; Viktor Kharazia; Maria Waldhoer; Chrissi J Ou; Stacy Taylor; Madeline Ferwerda; Dragana Cado; Jennifer L Whistler
Journal:  Curr Biol       Date:  2008-01-22       Impact factor: 10.834

6.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.

Authors:  Søren G F Rasmussen; Hee-Jung Choi; Daniel M Rosenbaum; Tong Sun Kobilka; Foon Sun Thian; Patricia C Edwards; Manfred Burghammer; Venkata R P Ratnala; Ruslan Sanishvili; Robert F Fischetti; Gebhard F X Schertler; William I Weis; Brian K Kobilka
Journal:  Nature       Date:  2007-10-21       Impact factor: 49.962

7.  Evidence for separate involvement of different mu-opioid receptor subtypes in itch and analgesia induced by supraspinal action of opioids.

Authors:  Tsugunobu Andoh; Yuichi Yageta; Mitsuhiro Konno; Tomomi Yamaguchi-Miyamoto; Hiroki Takahata; Hiroshi Nojima; Hideo Nemoto; Yasushi Kuraishi
Journal:  J Pharmacol Sci       Date:  2008-04-09       Impact factor: 3.337

8.  Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation.

Authors:  Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2007-10-18       Impact factor: 4.436

9.  Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling.

Authors:  Jean-Pierre Vilardaga; Viacheslav O Nikolaev; Kristina Lorenz; Sébastien Ferrandon; Zhenjie Zhuang; Martin J Lohse
Journal:  Nat Chem Biol       Date:  2008-01-13       Impact factor: 15.040

10.  dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm.

Authors:  S L Chen; H I Ma; J M Han; P L Tao; P Y Law; H H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-04       Impact factor: 11.205
View more
  23 in total

1.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

Review 2.  Signalling in response to sub-picomolar concentrations of active compounds: Pushing the boundaries of GPCR sensitivity.

Authors:  Srgjan Civciristov; Michelle L Halls
Journal:  Br J Pharmacol       Date:  2019-04-05       Impact factor: 8.739

3.  Sequence-Specific Regulation of Endocytic Lifetimes Modulates Arrestin-Mediated Signaling at the µ Opioid Receptor.

Authors:  Zara Y Weinberg; Amanda S Zajac; Tiffany Phan; Daniel J Shiwarski; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2017-02-02       Impact factor: 4.436

4.  BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Authors:  T V Khroyan; J Wu; W E Polgar; G Cami-Kobeci; N Fotaki; S M Husbands; L Toll
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

Review 5.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

Review 7.  [Pain inhibition by opioids-new concepts].

Authors:  C Stein
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

8.  In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.

Authors:  A Kuo; B D Wyse; W Meutermans; M T Smith
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

9.  Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.

Authors:  Rajendra Uprety; Tao Che; Saheem A Zaidi; Steven G Grinnell; Balázs R Varga; Abdelfattah Faouzi; Samuel T Slocum; Abdullah Allaoa; András Varadi; Melissa Nelson; Sarah M Bernhard; Elizaveta Kulko; Valerie Le Rouzic; Shainnel O Eans; Chloe A Simons; Amanda Hunkele; Joan Subrath; Ying Xian Pan; Jonathan A Javitch; Jay P McLaughlin; Bryan L Roth; Gavril W Pasternak; Vsevolod Katritch; Susruta Majumdar
Journal:  Elife       Date:  2021-02-08       Impact factor: 8.140

Review 10.  From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.

Authors:  Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner
Journal:  Trends Endocrinol Metab       Date:  2021-03-03       Impact factor: 12.015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.